BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martin P, Lau DT, Nguyen MH, Janssen HL, Dieterich DT, Peters MG, Jacobson IM. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. Clinical Gastroenterology and Hepatology 2015;13:2071-2087.e16. [DOI: 10.1016/j.cgh.2015.07.007] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang CY, He ZH, Ahir BK, Luo CP, Peng NF, Li LQ. Letter: should anti-viral therapy be recommended for individuals chronically infected with hepatitis B virus and at low risk of hepatocellular carcinoma? Aliment Pharmacol Ther 2017;45:181-2. [PMID: 27910145 DOI: 10.1111/apt.13814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Kim YA, Estevez J, Le A, Israelski D, Baatarkhuu O, Sarantuya T, Narantsetseg S, Nymadawa P, H Le R, Yuen MF, Dusheiko G, Rizzetto M, Nguyen MH. Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia. BMJ Open Gastroenterol 2016;3:e000119. [PMID: 27933202 DOI: 10.1136/bmjgast-2016-000119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Li Q, Song J, Huang Y, Li X, Zhuo Q, Li W, Chen C, Lu C, Qi X, Chen L. The Gamma-Glutamyl-Transpeptidase to Platelet Ratio Does not Show Advantages than APRI and Fib-4 in Diagnosing Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis B: A Retrospective Cohort Study in China. Medicine (Baltimore). 2016;95:e3372. [PMID: 27100421 DOI: 10.1097/md.0000000000003372] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 5.2] [Reference Citation Analysis]
4 Li C, Li ZC, Ma L, Li LQ, Zhong JH, Xiang BD, Gong WF. Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:749-56. [PMID: 32552297 DOI: 10.1080/17474124.2020.1784727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Jiang L, Wu X, He F, Liu Y, Hu X, Takeda S, Qing Y. Genetic Evidence for Genotoxic Effect of Entecavir, an Anti-Hepatitis B Virus Nucleotide Analog. PLoS One 2016;11:e0147440. [PMID: 26800464 DOI: 10.1371/journal.pone.0147440] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
6 Woldegiorgis AE, Erku W, Medhin G, Berhe N, Legesse M. Community-based sero-prevalence of hepatitis B and C infections in South Omo Zone, Southern Ethiopia. PLoS One 2019;14:e0226890. [PMID: 31887192 DOI: 10.1371/journal.pone.0226890] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Han MS, Park Y, Nah H, Kim HS. Comparison of the QIAGEN artus HBV QS-RGQ Assay With the Roche COBAS AmpliPrep/COBAS TaqMan HBV Assay for Quantifying Viral DNA in Sera of Chronic Hepatitis B Patients. Ann Lab Med 2017;37:248-53. [PMID: 28224771 DOI: 10.3343/alm.2017.37.3.248] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
8 Liu QM, Liu LL, Li XD, Tian P, Xu H, Li ZL, Wang LK. Silencing lncRNA TUG1 Alleviates LPS-Induced Mouse Hepatocyte Inflammation by Targeting miR-140/TNF. Front Cell Dev Biol 2020;8:616416. [PMID: 33644034 DOI: 10.3389/fcell.2020.616416] [Reference Citation Analysis]
9 Yu H, Yang H, Shi E, Tang W. Development and Clinical Application of Phosphorus-Containing Drugs. Med Drug Discov 2020;8:100063. [PMID: 32864606 DOI: 10.1016/j.medidd.2020.100063] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Xie Y, Yi W, Zhang L, Lu Y, Hao HX, Gao YJ, Ran CP, Lu HH, Chen QQ, Shen G, Wu SL, Chang M, Ping-Hu L, Liu RY, Sun L, Wan G, Li MH. Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigen-negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels. J Viral Hepat 2019;26 Suppl 1:42-9. [PMID: 31380591 DOI: 10.1111/jvh.13163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Dailey PJ, Elbeik T, Holodniy M. Companion and complementary diagnostics for infectious diseases. Expert Rev Mol Diagn 2020;20:619-36. [PMID: 32031431 DOI: 10.1080/14737159.2020.1724784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Nguyen MH, Yang HI, Le A, Henry L, Nguyen N, Lee MH, Zhang J, Wong C, Wong C, Trinh H. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study. J Infect Dis 2019;219:10-8. [PMID: 29982737 DOI: 10.1093/infdis/jiy391] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
13 Liu JH, Liao XW, Chen CH, Yao M, Li CC, Lin CT, Tsai CH, Chou WC, Hou HA, Huang SY, Wu SJ, Chen YC, Tien HF, Tang JL, Ko BS. Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study. Br J Haematol 2019;186:72-85. [PMID: 30919947 DOI: 10.1111/bjh.15884] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG. Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States. Open Forum Infect Dis 2019;6:ofy353. [PMID: 30931346 DOI: 10.1093/ofid/ofy353] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
15 Suzuki T, Yamada A, Komatsu D, Kurozumi M, Fujinaga Y, Ueda K, Miyagawa S, Kadoya M. Evaluation of splenic perfusion and spleen size using dynamic computed tomography: Usefulness in assessing degree of liver fibrosis: Dynamic CT for assessing degree of liver fibrosis. Hepatol Res 2018;48:87-93. [DOI: 10.1111/hepr.12900] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
16 Chen M, Jagya N, Bansal R, Frelin L, Sällberg M. Prospects and progress of DNA vaccines for treating hepatitis B. Expert Rev Vaccines. 2016;15:629-640. [PMID: 26652035 DOI: 10.1586/14760584.2016.1131615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Ogawa E, Yeo YH, Dang N, Le MH, Jeong D, Tran S, Henry L, Cheung R, Nguyen MH. Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States. JAMA Netw Open 2020;3:e201844. [PMID: 32271388 DOI: 10.1001/jamanetworkopen.2020.1844] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
18 Xiao Y, Zuo X, You Y, Luo H, Duan L, Zhang W, Li Y, Xie Y, Zhou Y, Ning W, Li T, Liu S, Zhu H, Jiang Y, Wu S, Zhao H. Investigation into the cause of mortality in 49 cases of idiopathic inflammatory myopathy: A single center study. Exp Ther Med 2016;11:885-9. [PMID: 26998007 DOI: 10.3892/etm.2016.3006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
19 Tong MJ, Pan CQ, Han SB, Lu DS, Raman S, Hu KQ, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Aliment Pharmacol Ther 2018;47:1181-200. [PMID: 29479728 DOI: 10.1111/apt.14577] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
20 Heidel KM, Dowd CS. Phosphonate prodrugs: an overview and recent advances. Future Med Chem 2019;11:1625-43. [PMID: 31469328 DOI: 10.4155/fmc-2018-0591] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
21 Qiu J, Xu B, Gong Q, Pan W, Liu C, Huang Z, Gu X, Liang G. Synthesis and Biological Evaluation of Matijin-Su Derivatives as Potential Antihepatitis B Virus and Anticancer Agents. Chem Biodivers 2016;13:1584-92. [PMID: 27451105 DOI: 10.1002/cbdv.201600113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Chang S, Wang LH, Chen BS. Investigating Core Signaling Pathways of Hepatitis B Virus Pathogenesis for Biomarkers Identification and Drug Discovery via Systems Biology and Deep Learning Method. Biomedicines. 2020;8. [PMID: 32878239 DOI: 10.3390/biomedicines8090320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Gentile G, Antonelli G. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses. 2019;11. [PMID: 31717647 DOI: 10.3390/v11111049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Lee HW, Park JY, Ahn SH. An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. Expert Rev Gastroenterol Hepatol 2016;10:177-86. [PMID: 26610256 DOI: 10.1586/17474124.2016.1125781] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
25 Sarpel D, Baichoo E, Dieterich DT. Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening. Expert Review of Anti-infective Therapy 2016;14:511-21. [DOI: 10.1586/14787210.2016.1174066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
26 Madeddu G, Fiore V, Melis M, Ortu S, Mannu F, Muredda AA, Garrucciu G, Bandiera F, Zaru S, Bagella P, Calvisi DF, Babudieri S. Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B. Sci Rep 2020;10:2014. [PMID: 32029790 DOI: 10.1038/s41598-020-58837-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Beloukas A, Geretti AM. Hepatitis B Virus Drug Resistance. In: Mayers DL, Sobel JD, Ouellette M, Kaye KS, Marchaim D, editors. Antimicrobial Drug Resistance. Cham: Springer International Publishing; 2017. pp. 1227-42. [DOI: 10.1007/978-3-319-47266-9_26] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
28 Zhang Y, Boktour MR. Effects of Share 35 Policy on Liver Transplantation Outcomes for Patients With Nonalcoholic Steatohepatitis. Prog Transplant 2019;29:248-53. [PMID: 31146627 DOI: 10.1177/1526924819854481] [Reference Citation Analysis]
29 Hoang JK, Yang HI, Le A, Nguyen NH, Lin D, Vu VD, Chaung K, Nguyen V, Trinh HN, Li J, Zhang JQ, Chen CJ, Nguyen MH. Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis. Medicine (Baltimore) 2016;95:e4433. [PMID: 27495067 DOI: 10.1097/MD.0000000000004433] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
30 Jacobson IM, Washington MK, Buti M, Thompson A, Afdhal N, Flisiak R, Akarca US, Tchernev KG, Flaherty JF, Aguilar Schall R, Myers RP, Subramanian GM, Mchutchison JG, Younossi Z, Marcellin P, Patel K. Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. Clinical Gastroenterology and Hepatology 2017;15:1087-1094.e2. [DOI: 10.1016/j.cgh.2017.01.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
31 Chen J, Hu Y, Chen L, Liu W, Mu Y, Liu P. The effect and mechanisms of Fuzheng Huayu formula against chronic liver diseases. Biomed Pharmacother 2019;114:108846. [PMID: 30965233 DOI: 10.1016/j.biopha.2019.108846] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
32 Rao SC, Ashraf I, Mir F, Samiullah S, Ibdah JA, Tahan V. Dual Infection with Hepatitis B and Epstein-Barr Virus Presenting with Severe Jaundice, Coagulopathy, and Hepatitis B Virus Chronicity Outcome. Am J Case Rep 2017;18:170-2. [PMID: 28202897 DOI: 10.12659/ajcr.901688] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
33 Yu XY, Zhao SS. Renal dysfunction in initially treated patients with chronic hepatitis B: Rate and risk factors. Shijie Huaren Xiaohua Zazhi 2016; 24(19): 3026-3031 [DOI: 10.11569/wcjd.v24.i19.3026] [Reference Citation Analysis]
34 Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33. [PMID: 32102898 DOI: 10.1128/cmr.00046-19] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 18.5] [Reference Citation Analysis]
35 Yang X, Ma Z, Zhou S, Weng Y, Lei H, Zeng S, Li L, Jiang H. Multiple Drug Transporters Are Involved in Renal Secretion of Entecavir. Antimicrob Agents Chemother 2016;60:6260-70. [PMID: 27503646 DOI: 10.1128/AAC.00986-16] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
36 Hayashi S, Isogawa M, Kawashima K, Ito K, Chuaypen N, Morine Y, Shimada M, Higashi-Kuwata N, Watanabe T, Tangkijvanich P, Mitsuya H, Tanaka Y. Droplet digital PCR assay provides intrahepatic HBV cccDNA quantification tool for clinical application. Sci Rep 2022;12:2133. [PMID: 35136096 DOI: 10.1038/s41598-022-05882-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Cobb BR, Valsamakis A. Chronic Hepatitis B, C, and D. Microbiol Spectr 2016;4. [PMID: 27726758 DOI: 10.1128/microbiolspec.DMIH2-0025-2015] [Reference Citation Analysis]
38 Li X, Xu H, Gao P. Diabetes Mellitus is a Risk Factor for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection in China. Med Sci Monit 2018;24:6729-34. [PMID: 30245503 DOI: 10.12659/MSM.911702] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
39 Wong S, Huynh D, Zhang F, Nguyen NQ. Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis. World J Hepatol 2017; 9(17): 791-796 [PMID: 28660013 DOI: 10.4254/wjh.v9.i17.791] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
40 Nguyen VH, Le AK, Trinh HN, Chung M, Johnson T, Wong C, Wong C, Zhang J, Li J, Levitt BS, Nguyen HA, Nguyen KK, Henry L, Cheung R, Nguyen MH. Poor Adherence to Guidelines for Treatment of Chronic Hepatitis B Virus Infection at Primary Care and Referral Practices. Clinical Gastroenterology and Hepatology 2019;17:957-967.e7. [DOI: 10.1016/j.cgh.2018.10.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
41 Liou IW, Nguyen MH. The Cascade of Care in Chronic Hepatitis B. Curr Hepatology Rep 2016;15:209-19. [DOI: 10.1007/s11901-016-0316-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
42 Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019;133:137-146. [PMID: 30341058 DOI: 10.1182/blood-2018-04-848044] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 11.8] [Reference Citation Analysis]
43 Li J, Chang MS, Tran TT, Nguyen MH. Management of Chronic Hepatitis B in Pregnancy. J Clin Gastroenterol 2017;51:789-95. [PMID: 28816860 DOI: 10.1097/MCG.0000000000000908] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
44 Li T, Liu F, Zhang L, Ye Q, Fan X, Xue Y, Wang L. Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs. Saudi J Gastroenterol 2018;24:30-6. [PMID: 29451182 DOI: 10.4103/sjg.SJG_228_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Gao X, Yang HI, Trinh H, Jeong D, Li J, Zhang J, Le A, Hoang J, Nguyen P, Henry L, Nguyen MH. Antiviral therapy and hepatocellular carcinoma risk in hepatitis B patients with cirrhosis. Eur J Gastroenterol Hepatol 2020;32:1207-11. [PMID: 32129773 DOI: 10.1097/MEG.0000000000001639] [Reference Citation Analysis]
46 Kao JH, Asselah T, Dou XG, Hamed K. Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model. J Gastroenterol Hepatol 2017;32:73-81. [PMID: 27515408 DOI: 10.1111/jgh.13512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
47 Shepperson OA, Cameron AJ, Wang CJ, Harris PWR, Taylor JA, Brimble MA. Thiol-ene enabled preparation of S-lipidated anti-HBV peptides. Org Biomol Chem 2021;19:220-32. [PMID: 33185215 DOI: 10.1039/d0ob01997f] [Reference Citation Analysis]
48 Pan HY, Pan HY, Song WY, Zheng W, Tong YX, Yang DH, Dai YN, Chen MJ, Wang MS, Huang YC, Zhang JJ, Huang HJ. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis. J Viral Hepat 2017;24 Suppl 1:29-35. [PMID: 29082652 DOI: 10.1111/jvh.12794] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
49 Zhao P, Qian X, Su C, Yang X, Bai X. Lamivudine vs placebo or no treatment in preventing the transmission of hepatitis B virus during pregnancy: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg 2020;114:121-30. [PMID: 31703121 DOI: 10.1093/trstmh/trz078] [Reference Citation Analysis]
50 Martin P. Immune-Tolerant Hepatitis B: Maybe a Misnomer but Still Hard to Treat. Hepatology 2019;69:2315-7. [PMID: 30964209 DOI: 10.1002/hep.30654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 Ndugga N, Lightbourne TG, Javaherian K, Cabezas J, Verma N, Barritt AS 4th, Bataller R. Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA. BMJ Open 2017;7:e013620. [PMID: 28336739 DOI: 10.1136/bmjopen-2016-013620] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
52 Ahn JC, Ahn J. Hepatitis B: Standard and Novel Treatment Options. Clin Liver Dis (Hoboken) 2018;12:19-23. [PMID: 30988904 DOI: 10.1002/cld.719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
53 Li S, Li S, Wu S, Chen L. Exosomes Modulate the Viral Replication and Host Immune Responses in HBV Infection. Biomed Res Int 2019;2019:2103943. [PMID: 31275965 DOI: 10.1155/2019/2103943] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
54 Lee H, Lee SY, Mtengezo JT, Makin M, Park JH, Thompson L. Cancer Screening and Diagnostic Tests in Global Contexts: Case Study and Concept Analysis. Asia Pac J Oncol Nurs 2019;6:86-93. [PMID: 30599021 DOI: 10.4103/apjon.apjon_59_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Liu K, Xiang X, Bao R, Chen R, Liu Y, Xie J, Guo Q, Bao S, Xie Q, Wang H. A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients. Sci Rep 2016;6:28779. [PMID: 27364728 DOI: 10.1038/srep28779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
56 Lin D, Yang HI, Nguyen N, Hoang J, Kim Y, Vu V, Le A, Chaung K, Nguyen V, Trinh H, Li J, Zhang J, Hsing A, Chen CJ, Nguyen MH. Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients. Aliment Pharmacol Ther. 2016;44:846-855. [PMID: 27549411 DOI: 10.1111/apt.13774] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
57 Thuener J. Hepatitis A and B Infections. Prim Care. 2017;44:621-629. [PMID: 29132524 DOI: 10.1016/j.pop.2017.07.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
58 Ye Q, Kam LY, Yeo YH, Dang N, Huang DQ, Cheung R, Nguyen MH. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. J Hepatol 2021:S0168-8278(21)02014-6. [PMID: 34474097 DOI: 10.1016/j.jhep.2021.08.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Fallon MB, Kanwal F, El-Serag HB. The Art and Science of Managing Liver Disease. Clin Gastroenterol Hepatol 2015;13:2029-30. [PMID: 26325399 DOI: 10.1016/j.cgh.2015.08.031] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
60 Zhang J, Ma J, Wang H, Guo L, Li J. Serum microRNA-30c levels are correlated with disease progression in Xinjiang Uygur patients with chronic hepatitis B. Braz J Med Biol Res 2017;50:e6050. [PMID: 28492809 DOI: 10.1590/1414-431X20176050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
61 Osiowy C, Coffin C, Andonov A. Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy. Curr Treat Options Infect Dis 2016;8:177-93. [PMID: 27547127 DOI: 10.1007/s40506-016-0080-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
62 Mehta AS, Lau DT, Wang M, Aslam A, Nasir B, Javaid A, Poongkunran M, Block TM. Application of the Doylestown algorithm for the early detection of hepatocellular carcinoma. PLoS One 2018;13:e0203149. [PMID: 30169533 DOI: 10.1371/journal.pone.0203149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
63 Bourlière M, Rabiega P, Ganne-carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grangé JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-alias M, Carrat F. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. The Lancet Gastroenterology & Hepatology 2017;2:177-88. [DOI: 10.1016/s2468-1253(16)30189-3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 30] [Article Influence: 12.6] [Reference Citation Analysis]
64 Okada M, Enomoto M, Kawada N, Nguyen MH. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Rev Gastroenterol Hepatol. 2017;11:1095-1104. [PMID: 28752768 DOI: 10.1080/17474124.2017.1361822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
65 Wei MT, Nguyen MH. Editorial: the durability of seroconversion of hepatitis B e antigen in the treatment of chronic hepatitis B with PEG-interferon alfa-2a. Aliment Pharmacol Ther 2018;47:1556-7. [PMID: 29878418 DOI: 10.1111/apt.14657] [Reference Citation Analysis]